Larimar Therapeutics, Inc.

NASDAQ:LRMR

7.57 (USD) • At close November 4, 2024
Bedrijfsnaam Larimar Therapeutics, Inc.
Symbool LRMR
Munteenheid USD
Prijs 7.57
Beurswaarde 483,015,962
Dividendpercentage 0%
52-weken bereik 2.18 - 13.68
Industrie Biotechnology
Sector Healthcare
CEO Dr. Carole S. Ben-Maimon M.D.
Website https://www.larimartx.com

An error occurred while fetching data.

Over Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company

Vergelijkbare Aandelen

IRIDEX Corporation logo

IRIDEX Corporation

IRIX

1.42 USD

Modular Medical, Inc. logo

Modular Medical, Inc.

MODD

2.23 USD

Aspira Women's Health Inc. logo

Aspira Women's Health Inc.

AWH

0.886 USD

Daxor Corporation logo

Daxor Corporation

DXR

9.133 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)